CHMP issues positive opinions for Aclasta and Velcade
This article was originally published in Scrip
Executive Summary
Novartis's Aclasta (zoledronic acid) and Janssen-Cilag's Velcade (bortezomib) have both received positive opinions from the EU's CHMP relating to extensions of their indications. The committee adopted a negative opinion, however, on extending the indications of Aventis Pharma's docetaxel products Taxotere and Docetaxel Winthrop.